tradingkey.logo

Illumina Inc

ILMN
119.720USD
-13.890-10.40%
Close 02/06, 16:00ETQuotes delayed by 15 min
18.32BMarket Cap
21.83P/E TTM

Illumina Inc

119.720
-13.890-10.40%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Illumina Inc

Currency: USD Updated: 2026-02-06

Key Insights

Illumina Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 136.64.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Illumina Inc's Score

Industry at a Glance

Industry Ranking
43 / 205
Overall Ranking
133 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Illumina Inc Highlights

StrengthsRisks
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 21.83, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.13M shares, decreasing 11.60% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.98K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.

Analyst Rating

Based on 20 analysts
Hold
Current Rating
136.636
Target Price
+2.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Illumina Inc is 7.76, ranking 70 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.16B, representing a year-over-year increase of 4.98%, while its net profit experienced a year-over-year increase of 78.61%.

Score

Industry at a Glance

Previous score
7.76
Change
0

Financials

9.14

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.13

Operational Efficiency

8.16

Growth Potential

7.16

Shareholder Returns

6.21

Illumina Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Illumina Inc is 8.76, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 21.83, which is 57.27% below the recent high of 34.33 and 189.18% above the recent low of -19.47.

Score

Industry at a Glance

Previous score
8.76
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 43/205
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Illumina Inc is 6.90, ranking 154 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 120.00, with a high of 195.00 and a low of 80.00.

Score

Industry at a Glance

Previous score
6.90
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts
Hold
Current Rating
136.636
Target Price
+2.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

91
Total
4
Median
7
Average
Company name
Ratings
Analysts
Illumina Inc
ILMN
20
Intuitive Surgical Inc
ISRG
36
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Illumina Inc is 6.55, ranking 131 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 144.28 and the support level at 106.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.39
Change
0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-6.975
Neutral
RSI(14)
27.940
Sell
STOCH(KDJ)(9,3,3)
6.880
Oversold
ATR(14)
6.409
Low Volatility
CCI(14)
-208.863
Oversold
Williams %R
94.585
Oversold
TRIX(12,20)
0.030
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
132.816
Sell
MA10
141.353
Sell
MA20
144.097
Sell
MA50
138.044
Sell
MA100
121.881
Sell
MA200
106.877
Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Illumina Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 105.45%, representing a quarter-over-quarter increase of 1.61%. The largest institutional shareholder is The Vanguard, holding a total of 14.28M shares, representing 9.35% of shares outstanding, with 9.21% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Capital World Investors
19.98M
+20.01%
The Vanguard Group, Inc.
Star Investors
14.55M
-3.50%
BlackRock Institutional Trust Company, N.A.
13.14M
-3.47%
State Street Investment Management (US)
6.00M
+6.81%
Sessa Capital
4.69M
-0.76%
Loomis, Sayles & Company, L.P.
4.29M
+1.46%
WCM Investment Management
4.18M
-5.53%
Corvex Management LP
3.83M
--
AQR Capital Management, LLC
3.40M
+3.10%
Geode Capital Management, L.L.C.
2.74M
-4.54%
1
2

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Illumina Inc is 6.49, ranking 58 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.46. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
6.49
Change
0
Beta vs S&P 500 index
1.46
VaR
+4.24%
240-Day Maximum Drawdown
+26.59%
240-Day Volatility
+45.36%

Return

Best Daily Return
60 days
+5.20%
120 days
+24.78%
5 years
+24.78%
Worst Daily Return
60 days
-10.40%
120 days
-10.40%
5 years
-14.63%
Sharpe Ratio
60 days
+0.01
120 days
+0.94
5 years
-0.33

Risk Assessment

Maximum Drawdown
240 days
+26.59%
3 years
+68.91%
5 years
+86.22%
Return-to-Drawdown Ratio
240 days
+1.03
3 years
-0.21
5 years
-0.16
Skewness
240 days
+1.98
3 years
+1.04
5 years
+0.86

Volatility

Realised Volatility
240 days
+45.36%
5 years
+44.67%
Standardised True Range
240 days
+3.30%
5 years
+6.01%
Downside Risk-Adjusted Return
120 days
+199.90%
240 days
+199.90%
Maximum Daily Upside Volatility
60 days
+30.08%
Maximum Daily Downside Volatility
60 days
+29.95%

Liquidity

Average Turnover Rate
60 days
+1.31%
120 days
+1.36%
5 years
--
Turnover Deviation
20 days
-30.51%
60 days
-5.18%
120 days
-1.32%

Peer Comparison

Healthcare Equipment & Supplies
Illumina Inc
Illumina Inc
ILMN
7.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
Align Technology Inc
ALGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI